Radiotherapy plus pembrolizumab for advanced urothelial carcinoma: results from the ARON-2 real-world study-Reference-Cited by-同舟云学术

Radiotherapy plus pembrolizumab for advanced urothelial carcinoma: results from the ARON-2 real-world study

Published:2024-08-27 Issue:1 Volume:14 Page:
ISSN:2045-2322
Container-title:Scientific Reports
language:en
Short-container-title:Sci Rep

Author:

Rizzo Mimma,Soares Andrey,Grande Enrique,Bamias Aristotelis,Kopp Ray Manneh,Lenci Edoardo,Buttner Thomas,Salah Samer,Grillone Francesco,de Carvalho Icaro Thiago,Tapia Jose Carlos,Gucciardino Calogero,Pinto Alvaro,Mennitto Alessia,Abahssain Halima,Rescigno Pasquale,Myint Zin,Takeshita Hideki,Spinelli Gian Paolo,Popovic Lazar,Vitale Maria Giuseppa,Fiala Ondrej,Giannatempo Patrizia,Zakopoulou Roubini,Carrozza Francesco,Massari Francesco,Monteiro Fernando Sabino Marques,Pace Maria Paola,Giannini Massimo,Roviello Giandomenico,Porta Camillo,Battelli Nicola,Kanesvaran Ravindran,Santoni Matteo

Publisher

Springer Science and Business Media LLC

Link

https://www.nature.com/articles/s41598-024-70182-3.pdf

Reference40 articles.

1. Meeks, J. J. et al. Checkpoint inhibitors in urothelial carcinoma-future directions and biomarker selection. Eur. Urol. 84, 473–483. https://doi.org/10.1016/j.eururo.2023.05.011 (2023).

2. Powles, T. et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 515, 558–562. https://doi.org/10.1038/nature13904 (2014).

3. Bellmunt, J. et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med 376, 1015–1026. https://doi.org/10.1056/NEJMoa1613683 (2017).

4. Fradet, Y. et al. Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up. Ann Oncol 30, 970–976. https://doi.org/10.1093/annonc/mdz127 (2019).

5. Vuky, J. et al. Long-term outcomes in KEYNOTE-052: Phase II study investigating first-line pembrolizumab in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer. J Clin Oncol 38, 2658–2666. https://doi.org/10.1200/JCO.19.01213 (2020).